Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 634

1.

Yogurt consumption and risk of conventional and serrated precursors of colorectal cancer.

Zheng X, Wu K, Song M, Ogino S, Fuchs CS, Chan AT, Giovannucci EL, Cao Y, Zhang X.

Gut. 2019 Jun 17. pii: gutjnl-2019-318374. doi: 10.1136/gutjnl-2019-318374. [Epub ahead of print] No abstract available.

PMID:
31209182
2.

A Phase 1b/2 Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer.

Harding JJ, Zhu AX, Bauer TM, Choueiri TK, Drilon A, Voss MH, Fuchs CS, Abou-Alfa GK, Wijayawardana SR, Wang XA, Moser BA, Uruñuela A, Wacheck V, Bendell JC.

Clin Cancer Res. 2019 May 29. pii: clincanres.4010.2018. doi: 10.1158/1078-0432.CCR-18-4010. [Epub ahead of print]

PMID:
31142504
3.

Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer.

Yuan C, Renfro L, Ambadwar PB, Ou FS, McLeod HL, Innocenti F, Meyerhardt JA, Wolpin BM, Goldberg RM, Grothey A, Fuchs CS, Ng K.

Cancer Causes Control. 2019 Jul;30(7):757-765. doi: 10.1007/s10552-019-01183-1. Epub 2019 May 18.

PMID:
31104167
4.

Identification of Plasma Lipid Metabolites Associated with Nut Consumption in US Men and Women.

Malik VS, Guasch-Ferre M, Hu FB, Townsend MK, Zeleznik OA, Eliassen AH, Tworoger SS, Karlson EW, Costenbader KH, Ascherio A, Wilson KM, Mucci LA, Giovannucci EL, Fuchs CS, Bao Y.

J Nutr. 2019 May 16. pii: nxz048. doi: 10.1093/jn/nxz048. [Epub ahead of print]

PMID:
31095304
5.

Acne Treatment With Light Absorbing Gold Microparticles and Optical Pulses: An Open-Label European Multi-Centered Study in Moderate to Moderately Severe Acne Vulgaris Patients.

Fuchs CSK, Bay C, Adatto M, Lomholt H, Haedersdal M.

Lasers Surg Med. 2019 May 14. doi: 10.1002/lsm.23099. [Epub ahead of print]

PMID:
31090089
6.

Dietary intake of fiber, whole grains and risk of colorectal cancer: An updated analysis according to food sources, tumor location and molecular subtypes in two large US cohorts.

He X, Wu K, Zhang X, Nishihara R, Cao Y, Fuchs CS, Giovannucci EL, Ogino S, Chan AT, Song M.

Int J Cancer. 2019 May 1. doi: 10.1002/ijc.32382. [Epub ahead of print]

PMID:
31044426
7.

Correction: Gene Regulatory Network Analysis Identifies Sex-Linked Differences in Colon Cancer Drug Metabolism.

Lopes-Ramos CM, Kuijjer ML, Ogino S, Fuchs CS, DeMeo DL, Glass K, Quackenbush J.

Cancer Res. 2019 Apr 15;79(8):2084. doi: 10.1158/0008-5472.CAN-19-0678. No abstract available.

PMID:
30987980
8.

Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial.

Ng K, Nimeiri HS, McCleary NJ, Abrams TA, Yurgelun MB, Cleary JM, Rubinson DA, Schrag D, Miksad R, Bullock AJ, Allen J, Zuckerman D, Chan E, Chan JA, Wolpin BM, Constantine M, Weckstein DJ, Faggen MA, Thomas CA, Kournioti C, Yuan C, Ganser C, Wilkinson B, Mackintosh C, Zheng H, Hollis BW, Meyerhardt JA, Fuchs CS.

JAMA. 2019 Apr 9;321(14):1370-1379. doi: 10.1001/jama.2019.2402.

PMID:
30964527
9.

Calcium intake and colon cancer risk subtypes by tumor molecular characteristics.

Keum N, Liu L, Hamada T, Qian ZR, Nowak JA, Cao Y, da Silva A, Kosumi K, Song M, Nevo D, Wang M, Chan AT, Meyerhardt JA, Fuchs CS, Wu K, Ogino S, Nishihara R, Zhang X.

Cancer Causes Control. 2019 Jun;30(6):637-649. doi: 10.1007/s10552-019-01165-3. Epub 2019 Apr 8.

PMID:
30963391
10.

FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial.

Cleary JM, Horick NK, McCleary NJ, Abrams TA, Yurgelun MB, Azzoli CG, Rubinson DA, Brooks GA, Chan JA, Blaszkowsky LS, Clark JW, Goyal L, Meyerhardt JA, Ng K, Schrag D, Savarese DMF, Graham C, Fitzpatrick B, Gibb KA, Boucher Y, Duda DG, Jain RK, Fuchs CS, Enzinger PC.

Cancer. 2019 Mar 26. doi: 10.1002/cncr.32029. [Epub ahead of print]

PMID:
30913304
11.

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.

Bang YJ, Kang YK, Catenacci DV, Muro K, Fuchs CS, Geva R, Hara H, Golan T, Garrido M, Jalal SI, Borg C, Doi T, Yoon HH, Savage MJ, Wang J, Dalal RP, Shah S, Wainberg ZA, Chung HC.

Gastric Cancer. 2019 Jul;22(4):828-837. doi: 10.1007/s10120-018-00909-5. Epub 2019 Mar 25.

PMID:
30911859
12.

Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk.

Hamada T, Yuan C, Yurgelun MB, Perez K, Khalaf N, Morales-Oyarvide V, Babic A, Nowak JA, Rubinson DA, Giannakis M, Ng K, Kraft P, Stampfer MJ, Giovannucci EL, Fuchs CS, Ogino S, Wolpin BM.

Br J Cancer. 2019 Apr;120(8):848-854. doi: 10.1038/s41416-019-0426-5. Epub 2019 Mar 14.

PMID:
30867564
13.

Omitted Disclosures of Potential Conflicts of Interest in Articles Published in JAMA Oncology.

Fuchs CS.

JAMA Oncol. 2019 Mar 7. doi: 10.1001/jamaoncol.2019.0235. [Epub ahead of print] No abstract available.

PMID:
30844040
14.

Transfollicular delivery of gold microparticles in healthy skin and acne vulgaris, assessed by in vivo reflectance confocal microscopy and optical coherence tomography.

Fuchs CSK, Ortner VK, Mogensen M, Philipsen PA, Haedersdal M.

Lasers Surg Med. 2019 Mar 5. doi: 10.1002/lsm.23076. [Epub ahead of print]

PMID:
30835885
15.

Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.

Kosumi K, Hamada T, Zhang S, Liu L, da Silva A, Koh H, Twombly TS, Mima K, Morikawa T, Song M, Nowak JA, Nishihara R, Saltz LB, Niedzwiecki D, Ou FS, Zemla T, Mayer RJ, Baba H, Ng K, Giannakis M, Zhang X, Wu K, Giovannucci EL, Chan AT, Fuchs CS, Meyerhardt JA, Ogino S.

Eur J Cancer. 2019 Apr;111:82-93. doi: 10.1016/j.ejca.2019.01.022. Epub 2019 Mar 1.

PMID:
30826660
16.

KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer.

Bang YJ, Van Cutsem E, Fuchs CS, Ohtsu A, Tabernero J, Ilson DH, Hyung WJ, Strong VE, Goetze TO, Yoshikawa T, Tang LH, Hwang PMT, Webb N, Adelberg D, Shitara K.

Future Oncol. 2019 Mar;15(9):943-952. doi: 10.2217/fon-2018-0581. Epub 2019 Feb 19.

17.

Calcium Intake and Risk of Colorectal Cancer According to Tumor-infiltrating T Cells.

Yang W, Liu L, Keum N, Qian ZR, Nowak JA, Hamada T, Song M, Cao Y, Nosho K, Smith-Warner SA, Zhang S, Masugi Y, Ng K, Kosumi K, Ma Y, Garrett WS, Wang M, Nan H, Giannakis M, Meyerhardt JA, Chan AT, Fuchs CS, Nishihara R, Wu K, Giovannucci EL, Ogino S, Zhang X.

Cancer Prev Res (Phila). 2019 May;12(5):283-294. doi: 10.1158/1940-6207.CAPR-18-0279. Epub 2019 Feb 13.

PMID:
30760501
18.

Sedentary Behaviors, TV Viewing Time, and Risk of Young-Onset Colorectal Cancer.

Nguyen LH, Liu PH, Zheng X, Keum N, Zong X, Li X, Wu K, Fuchs CS, Ogino S, Ng K, Willett WC, Chan AT, Giovannucci EL, Cao Y.

JNCI Cancer Spectr. 2018 Nov;2(4):pky073. doi: 10.1093/jncics/pky073. Epub 2019 Jan 25.

19.

Low-Carbohydrate Diet Score and Macronutrient Intake in Relation to Survival After Colorectal Cancer Diagnosis.

Song M, Wu K, Meyerhardt JA, Yilmaz O, Wang M, Ogino S, Fuchs CS, Giovannucci EL, Chan AT.

JNCI Cancer Spectr. 2018 Nov;2(4):pky077. doi: 10.1093/jncics/pky077. Epub 2019 Jan 28.

20.

Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance).

Morales-Oyarvide V, Yuan C, Babic A, Zhang S, Niedzwiecki D, Brand-Miller JC, Sampson-Kent L, Ye X, Li Y, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Wu K, Willett WC, Giovannucci EL, Wolpin BM, Meyerhardt JA, Fuchs CS, Ng K.

J Natl Cancer Inst. 2019 Feb 1;111(2):170-179. doi: 10.1093/jnci/djy098.

Supplemental Content

Loading ...
Support Center